Eikon ‍Therapeutics targets $908 million valuation in US IPO

Core Viewpoint - Eikon Therapeutics is aiming for a valuation of up to $908.2 million in its upcoming U.S. initial public offering, indicating a resurgence in biotech listings [1] Company Summary - Eikon Therapeutics is a drug developer that is preparing for an initial public offering (IPO) in the U.S. market [1] - The targeted valuation of $908.2 million reflects the company's growth potential and investor interest in the biotech sector [1] Industry Summary - The biotech industry is experiencing a comeback in public listings, suggesting renewed investor confidence and market activity [1]